Digest Network Come funziona
Network
/
Società
Ne
Non verificato

Newron Pharmaceuticals S.p.A.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

23 comunicati stampa

Guarda tutti i comunicati
24/03/2026
Telefonia e Varie
Mercato azionario
Scienza
Psichiatria
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Newron Presents 2025 Financial Results and Provides 2026 Outlook
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
20/03/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
19/03/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
18/03/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Finanza
Sanità
Salute
Organizzazione Aziendale
Banca
Associazioni/Professionisti
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
16/02/2026
Mercato azionario
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
03/02/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
07/01/2026
Mercato del lavoro
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
06/01/2026
Industria
Psichiatria
Salute
Scienza
Farmaceutica
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
22/12/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Eventi
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Psichiatria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
Fonte
Newron Pharmaceuticals S.p.A.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0